For the quarter ending 2026-03-31, DMAC had -$10,779K decrease in cash & cash equivalents over the period. -$9,090K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total operating expenses, excluding share-based compensation | 9,660 | 8,021 | 8,017 | - |
| Research And Development Expense | - | 528 | - | - |
| General And Administrative Expense | - | 664 | - | - |
| Total share-based compensation | 822 | 1,192 | 1,016 | - |
| Operating loss | -10,482 | -9,213 | -9,033 | - |
| Interest income | 470 | 472 | 440 | - |
| Other expense, net | 23 | 10 | - | - |
| Other income (expense), net | - | - | -21 | - |
| Income tax expense | 7 | 10 | 6 | - |
| Net loss | -10,042 | -8,740 | -8,620 | -15,406 |
| Share-based compensation | 822 | 1,192 | 1,016 | 1,638 |
| Amortization of discounts on marketable securities | 190 | 252 | 249 | 441 |
| Non-cash lease expense | 22 | 21 | 21 | 40 |
| Depreciation | 11 | 11 | 18 | 14 |
| Amounts receivable | 43 | -2 | 99 | -75 |
| Prepaid expenses and other assets | 250 | 36 | -235 | 453 |
| Deposits | 0 | -200 | 0 | -1,108 |
| Accounts payable | 1,818 | -445 | 659 | 321 |
| Accrued liabilities | -1,230 | 282 | 469 | -1,643 |
| Net cash used in operating activities | -9,082 | -7,765 | -6,550 | -14,747 |
| Purchase of marketable securities | 18,896 | 8,054 | 34,854 | 16,370 |
| Maturities and sales of marketable securities | 16,790 | 16,055 | 9,104 | 31,967 |
| Purchase of property and equipment | 8 | 6 | 16 | 18 |
| Net cash provided by (used in) investing activities | -2,114 | 7,995 | -25,766 | 15,579 |
| Proceeds from the sale of common shares, net of offering costs | - | 11,755 | 31,527 | 0 |
| Proceed from the exercise of common stock options | 420 | 282 | 465 | 257 |
| Deferred financing costs, net | - | -56 | 456 | - |
| Principal payments on finance lease obligations | 3 | 2 | 3 | 5 |
| Net cash provided by financing activities | 417 | 12,091 | 31,533 | 252 |
| Net increase (decrease) in cash and cash equivalents | -10,779 | 12,321 | -783 | 1,084 |
| Cash and cash equivalents at beginning of period | 15,647 | 3,326 | 3,025 | - |
| Cash and cash equivalents at end of period | 4,868 | 15,647 | 3,326 | - |
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC)